People's Fu pharmaceutical subsidiary Anli Shengtan tablets to obtain drug registration approval notice

On December 28th, Wuhan People's Fu Pharmaceutical Co., Ltd. ("Wuhan People's Fu"), a subsidiary of People's Fu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Wuhan People's Fu", holds 98.33 percent of its shares, and Yichang People's Pharmaceutical Co., Ltd., a controlling subsidiary, holds 1.67 percent of its shares).
, Wuhan People's Fund, submitted a drug registration application to the Drug Review Center of the State Drug Administration in January 2019, and has invested about RMB 8 million in research and development so far.
is used to treat patients with Pulmonary Hypertension (WHO Group 1) with WHO Level II or III symptoms to improve motor ability and delay clinical deterioration.
According to Milnet statistics, in 2019 Anli shengtan tablets in China's cities, counties and townships three terminal public hospital sales of about 26 million yuan, sales in urban pharmacies about 40 million yuan, the main manufacturers GLAXOSMITHKLINE INC., Jiangsu Hausen Pharmaceutical Group Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd.